Skip to main content
. 2014 Sep 11;106(9):dju204. doi: 10.1093/jnci/dju204

Figure 2.

Figure 2.

Western blot analysis of epidermal growth factor receptor (EGFR) phosphorylation (p-EGFR) and cleavage of poly(ADP-ribose) polymerase (PARP) and caspase 3 (Casp-3). A) H1975 and H3255 cells were treated with erlotinib and ibrutinib with the dose as indicated. Phospho-Y1068 and total EGFR were determined at 24 hours after treatment. B) HCC827, H292, and A549 cells were treated with erlotinib or ibrutinib at the doses as indicated. Cell lysates were harvested for protein phosphorylation analyses at 24 hours. Note, for A549 cells, 10ng/ml EGF was added to the cells to activate EGFR 15min before harvesting cells. C) HCC827 cells were treated with 0.5 μM erlotinib or 0.5 μM ibrutinib and tested for EGFR phosphorylation at different time points as indicated. D) HCC827 cells were treated with ibrutinib and tested for EGFR phosphorylation and caspase-3 and PARP1 cleavages at 48 hours.